Clinical Study of Jianpi Yifei Decoction Combined with Nikethamide in the Treatment of Chronic Obstructive Pulmonary Disease Patients with Respiratory Failure

Abstract

Background To explore the clinical effects of Jianpi Yifei Decoction combined with nikethamide in the treatment of patients with chronic obstructive pulmonary disease (COPD) and respiratory failure. Methods From January 2020 to January 2022, 126 patients with COPD with respiratory failure were randomly divided into a control group and an observation group, with 63 cases in each group. Patients in control group were treated with nikethamide for 14 days, on the basis of which patients in observation group were additionally treated with Jianpi Yifei Decoction for 14 days. Clinical symptoms, lung function, blood gas indexes, and serum factor levels were determined by APACHE II and mMRC scores, pulmonary function instrument, blood gas analyzer and ELISA kits. Results After treatment, the scores of APACHE II and mMRC scores, as well as levels of partial pressure of carbon dioxide (PaCO2) in arterial blood, C-reactive protein (CRP), tumour necrosis factor-α (TNF-α), interleukin-8 (IL-8), and procalcitonin (PCT) were significantly lowered, and those in the observation group were remarkably lower than those in the control group. Levels of forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), peak expiratory flow rate (PEF), arterial partial pressure (PaO2) and blood oxygen saturation (SaO2) were soared after treatment, with the levels in the observation group higher than those in the control group. Conclusion Jianpi Yifei Decoction combined with nikethamide alleviates clinical symptoms, improves lung function and blood gas analysis indexes, and attenuates the body's inflammatory response of patients with COPD and respiratory failure.